Zacks Investment Research on MSN
MRK, Daiichi's BLA for ADC drug gets FDA priority tag in lung cancer
Merck MRK and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) ...
Patritumab deruxtecan's BLA withdrawal was due to HERTHENA-Lung02 trial's unsatisfactory overall survival results, despite progression-free survival significance. The HERTHENA-Lung02 trial compared ...
Pharmaceutical Technology on MSN
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
The FDA has scheduled a decision date for 10 October 2026 under the Prescription Drug User Fee Act.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results